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Summary Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of
treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy.
There were 40 responders (R) and 41 non-responders (NR) at 3 months from the start of treatment. Plasma
oestrone concentrations were higher in non-responders at 1 and 2 months after starting AG (Means: NR
106+50, R 84+26pmoll1-, P<0.05; highest value NR 121+51, R 99+24pmoll1, P<0.05). High oestrone
levels were correlated with bulky liver secondaries, but not with age, tumour-free interval, time from last
menstrual period, time from relapse to start of AG or body weight. Non-responders had higher mean pro-
lactin levels on treatment (prolactin <SOOmIUl-l in 14/40 NR, 2/35 R, P<0.01). High oestrone or prolactin
levels were present in 28/41 NR and 6/40 R (P<0.001). Dehydroepiandrosterone sulphate suppression did not
differ between R and NR. The differences in peripheral endocrine environment in non-responding patients
suggest that oestrogen metabolism may differ in non-responding patients and that sub-groups could be
selected for rational endocrine therapy.
There have been many attempts to correlate
peripheral hormone changes with response to
endocrine ablative or additive therapy in advanced
postmenopausal breast cancer (Atkins et al., 1968;
Bates et al., 1976; Bulbrook et al., 1958; Irvine et
al., 1961; Juret & Hayem, 1961; McAllister et al.,
1960; Swyer et al., 1961). These studies have used
urinary assays or not measured the main oestrogen
in postmenopausal plasma, oestrone. They have not
shown a correlation with response, apart from a
urinary discriminant function which occurs in many
conditions and is probably due to stress (Durant &
Miller, 1973). Although oestrogen receptor
positivity of the primary or secondary tumour
correlates with response to endocrine therapy, only
50% of oestrogen receptor-positive tumours
respond (McGuire, 1978; Hawkins et al., 1980).
We have measured peripheral hormones in post-
menopausal patients with advanced breast cancer
receiving treatment with aminoglutethimide and
hydrocortisone (Smith et al., 1978). This treatment
suppresses oestrone (E1), oestradiol (E2) and
dehydroepiandrosterone sulphate (DHAS) levels
(Santen et al., 1977a). The aim was to see if
hormone suppression correlated with response to
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therapy and if any particular hormone pattern was
associated with failure to respond. In this regard it
is interesting to note that Worgul et al. (1982) have
shown that peripheral oestrone (E1) and dehydro-
epiandrosterone levels may rise 1-2 years after
adrenalectomy in patients with breast cancer and
this may be related to recurrence of the tumour.
Aminoglutethimide inhibits the conversion of
cholesterol to pregnenolone by the 20,22 desmolase
complex, an early step in the adrenal synthesis of
androgens (Dexter et al., 1967). Aminoglutethimide
is usually combined with a replacement dose of
hydrocortisone to prevent a reflex rise of ACTH
that may overcome the block (Santen et al., 1977a).
An additional action of aminoglutethimide is
inhibition of the peripheral conversion of androgens
to oestrogens by aromatase, the main source of
oestrogens in the postmenopausal woman (Santen
et al., 1978; Grodin et al., 1973).
Patients and methods
Eighty-one patients with advanced postmenopausal
breast cancer were studied for the effects of amino-
glutethimide (AG) on plasma hormones. These
patients all had progressing disease and had been
entered into a phase II study of AG in advanced
breast cancer (Harris et al., 1982), a randomised
study of tamoxifen versus AG (Smith et al., 1981)
or a study of incremental dose AG (Harris et al.,
1982b).
The ages ranged from 29-78 years, tumour-free
interval from 0-216 months and time from last
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menstrual period from 1 year to 35 years. Further
clinical details are given in Results. Previous
treatment, if any, was endocrine therapy
(tamoxifen, androgens or oophorectomy) in 53
patients and adjuvant chemotherapy in 24 patients.
Seventeen patients had received no previous
therapy.
Drug administration
AG was given as 250mg three times a day for 2
weeks, with 20mg hydrocortisone twice a day at
8am and 8pm. After 2 weeks the dose of AG was
increased to 250mg four times a day if there were
no side-effects. If side-effects occurred, the dosage
was decreased, which resulted in a subsidence of
side-effects usually within 4-6 weeks. Patients who
could not tolerate the drug were withdrawn and are
not included in this study.
Response
Response was assessed by standard UICC criteria
at 3 months or sooner if disease progressed
(Hayward et al., 1977). There were 41 patients with
progressive disease (non-responders, NR) and 40
patients with a response to therapy (responders, R).
Thirty patients had a partial response for >3
months, 2 patients had a complete response and 8
patients had a stable disease for >6 months.
Blood samples
Blood was taken before treatment in 29 non-
responders and 17 responders. Samples were taken
at monthly intervals after the start of treatment,
- 3h after the morning dose of AG, in all 81
patients. Plasma was stored at -20°C until
analysis. Two or more samples were taken from 32
responders, but only 21 non-responders, mainly
because of progressive disease at 1 month (10
patients stopped) or 2 months (another 11 stopped).
Hormone assays
Steroid hormones were measured by radioimmuno-
assay (RIA) according to previously described
methodologies: testosterone, 170H progesterone,
4A-androstenedione and DHAS (Harris et al.,
1982a); oestrone and oestradiol (Harris et al.,
1982b). Sex hormone binding globulin was
measured according to the nmethod of Iqbal &
Johnson (1977). Prolactin was measured by RIA
using reagents provided by the WHO Matched
Reagent Scheme, except for 125I-prolactin, which
was obtained from the North East Thames
Regional Immunoassay Unit. The methodology
used is described in the WHO Manual (WHO
1981).
Results
Oestrogens
Oestrone Oestrone levels were suppressed
significantly in responders (52.6% of baseline
+30.5, n= 17) and non-responders (67.8% of
baseline +33.6, n=26) at 1 month from start of
treatment. Paired t-tests between subsequent time
points for patients with 2 or more samples showed
no significant differences in oestrone values with
time in individual patients, either responders or
non-responders (Figure 1). At each time point up to
3 months, the non-responders had higher oestrone
values than responders (Figure 1).
Since oestrone values did not change significantly
with time on treatment in individuals, the mean
oestrone value was calculated for patients with 2 or
more samples. Individual values for patients who
had only 1 on treatment sample were included with
mean values or highest values for patients having
multiple samples. Mean oestrone levels on
treatment were significantly lower in the 40
responders than in the 41 non-responders (Table I).
The highest oestrone level on treatment was also
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Figure 1 Oestrone levels before and during treatment
with aminoglutethimide. Non responders (0),
responders (0). Bars represent standard error of the
mean. *P= <0.05, **P= <0.01, unpaired t-test
between responders and non-responders at each time
point. Numerators are the numbers of patients who
had plasma samples at the times indicated, and the
denominators are the number of patients still on
treatment at the time indicated.
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Table I Hormone values in responders versus non-responders to aminoglutethimide
Responders (40) A Non-Responders (41) B RvsNR
Pre Post Pre Post
Hormone Mean s.d. (n) Mean s.d. (n) P Mean s.d. (n) Mean s.d. (n) P Pre Post
Mean Oestrone
pmoll-' 150 59 (17) 84 26 (40) <0.001 172 77 (26) 106 50 (41) <0.001 NS <0.05
Highest Oestrone 99 25 121 50 - - <0.05
Lowest Oestrone 73 30 90 52 - - 0.07
Oestradiol 38 19 (13) 19 20 (35) <0.001 44 32 (25) 21 16 (38) <0.001 NS NS
DHAS (mean)
pmolIP1 1.14 79 (16) 0.34 0.33 (40) <0.001 1.33 0.66 (27) 0.32 0.24 (40) <0.001 NS NS
Testosterone
nmol I` 1.17 0.57 (8) 0.83 0.53 (19) <0.05 1.44 0.65 (15) 1.12 0.78 (25) <0.05 NS NS
170H progeste-
rone nkmolIP1 2.97 2.87 (14) 2.72 3.5 (15) NS
A4 androstene-
dione nmolI` 2.9 1.26 (14) 2.7 2.02 (15) NS
SHBG nmolI` 64 30 (35) 73 32 (40) NS
DHT bound
Prolactin
(mlUlI1) 232 164 (15) 308 207 (35) NS 356 322 (27) 487 496 (40) NS NS <0.05
% Suppression Mean s.d. n Mean s.d. n RvsNR
Oestrone 52.6 30.5 (17) 67.8 33.6 (25) NS
Oestradiol 36.1 21.8 (13) 50.6 42.2 (25) NS
DHAS 34.6 30 (16) 25.3 19.6 (26) NS
Testosterone 41.2 31.9 (8) 71.7 38.9 (15) NS
NS=not significant.
Column A: Pre versus post values in responders.
Column B: Pre versus post values in non-responders.
RvsNR: Pre values compared in responders versus non-responders.
Post values compared in responders versus non-responders.
significantly higher in non-responders (Figure 2);
18/41 non-responders had oestrone >120pmoll-1
(mean value for highest oestrone in non-
responders). The lowest oestrone on treatment was
lower in responders, but of borderline significance
(P=0.07).
Patient histories were examined of clinical
features that might be associated with levels of
oestrone. There was no correlation with age, years
since the menopause or tumour-free interval with
response (Table II). The mean body weight in
responders was 65.2kg± 10.8 (s.d.) and 57.9kg±9.2
(s.d.) in non-responders (P<0.002). The mean body
weight in the 18 non-responders with high oestrone
was 59.2kg±9.6 (s.d.) and in the other 23 non-
responders it was 56.9kg±9 (s.d.) (P=0.44).
Similarly, there was no relationship between
response and time from first recurrence to the time
of starting treatment with AG (Table III). The non-
responders with high oestrone did not differ from
other non-responders, or responders with respect to
age, years since menopause, tumour-free interval or
time of starting AG.
However, there was a significant association of
high oestrogen with bulky liver secondaries (i.e.
more than 1/3 of the liver involved on isotope scan,
palpable liver, and raised alkaline phosphatase and
aspartate transaminase): 6/9 patients with bulky
liver secondaries had oestrone levels higher than
120pmoll-1, compared with 16/72 patients without
bulky liver secondaries (X2 7.98, P<0.01). If
patients with bulky liver secondaries were excluded
from analysis, 3/38 responders and 13/34 non-
responders had oestrone greater than 120pmollP1
(X2 9.55, P<0.01). Thus, liver secondaries did not
account for the majority of patients with high
oestrone.
Oestradiol Oestradiol Jevels were suppressed to a
similar extent to oestrone and although percentage
suppression was less in non-responders, this was
not significant.
Androgens
Dehydroepiandrosterone sulphate (DHAS) The
mean levels on treatment were suppressed to similar588 A.L. HARRIS et al.
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Figure 3 DHAS levels before and during treatment
with aminoglutethimide. (0) Non-responders; (0)
respondets; bars represent s.e. The numerators are the
numbers of patients who had plasma samples
measured at the times indicated, and the denominators
are the numbers of patients still on treatment at the
time indicated.
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Figure 2 Highest oestrone values on treatment with
aminoglutethimide. Each point is the highest result for
an individual patient on treatment with AG for >,1
month. (0) patients with bulky liver secondaries; (0)
patients without bulky liver secondaries. P= <0.05,
unpaired t-test.
levels in responders (0.34pmoll-1+0/33 s.d., n=40)
and in non-responders (0.32pmoll-1 +0.24 s.d.,
n =40).
The numbers of patients showing suppression
below the lower limit of detection (0.05,umoll- ') at
any time on treatment were similar in responders
(17/40) and non-responders (12/40). At each month
from the start of treatment there was no significant
difference in DHAS levels between responders and
non-responders (Figure 3). Percentage suppression
did not differ between the two groups of patients
(Table I).
Testosterone Testosterone levels were suppressed
by treatment. Mean levels on treatment and
suppression of testosterone as a percentage of
baseline values did not differ significantly between
responders and non-responders (Table I).
A4 Androstenedione and 17 OH progesterone The
levels of these hormones did not differ between
responders and non-responders (Table I). The range
of A4 androstenedione in non-responders was 0.7-
7.3nmoll- 1, and 3/4 highest values were in the
patients with bulky liver secondaries (7.5, 5.3,
3.3 nmol -1).
Sex-hormone-binding globulin (SHBG)
SHBG levels on treatment were not significantly
different in responders and non-responders (Table
I). Because of the effects of tamoxifen on SHBG
(Sakai et al., 1978), the values of SHBG before
treatment were assessed separately in those
receiving tamoxifen in the previous 2 months (26
patients) and those not receiving tamoxifen in the
previous 2 months (17).
Ten of 11 patients with SHBG levels >95nmol
DHT bound 1-l had received tamoxifen in the
previous 2 months, compared with 16/32 patients
with SHBG <95nmol DHT bound I1 (X2 5.73,
P<0.02). In the 10 patients, SHBG levels fell from
119+16.9 (s.d.) to 98+29 (s.d.) nmol DHT bound
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Table II Clinical features associated with high oestrone
Non-responders
Responders Non-responders High oestrone
n 40 (%) 41 (%) 18 (%)
AGE (Years)
<40-50 8 (20) 11 (27) 3 (16)
51-60 18 (45) 18 (44) 9 (50)
61->70 14 (35) 12 (29) 6 (34)
TFI (months)
0-12 10 (25) 18 (44) 9 (50)
13-24 10 (25) 6 (14) 3 (16)
>25 20 (50) 17 (42) 6 (34)
LMP (years)
<2 6 (15) 6 (15) 1 (6)
2-5 11 (28) 16 (39) 6 (33)
6-10 8 (20) 5 (12) 4 (22)
>10 15 (37) 14 (34) 7 (39)
SITES
Soft tissue/nodes 27 (68) 28 (68) 13 (72)
Bone 32 (80) 26 (63) 13 (72)
Liver* 2 (5) 7 (17) 5 (28)
Lung/pleura 9 (22) 13 (32) 4 (22)
WEIGHT (kg)
40-55 8 (20) 18 (44) 7 (39)
56-65 12 (30) 14 (34) 7 (39)
66-75 13 (33) 7 (17) 3 (17)
>75 7 (17) 2 (5) 1 (5)
*Significant difference betweeen non-responders high oestrone and
other groups.
Table MI Time from first metastasis to start of treatment with
aminoglutethimide
The percentage expressed at each time is cumulative frequency including all
preceeding patients started on AG. n is the number of patients started
during the time period shown.
Timefrom 1st Non-responders
metastasis to Responders Non-responders high oestrone
start ofAG 40 41 18
(m=months, y=years) n (%) n (%) n (%)
0-3 m 14 (35) 15 (36) 5 (28)
4m-1 y 4 (45) 7 (54) 3 (45)
1 y I m-2y 6 (60) 9 (75) 4 (77)
2y I m-4y 10 (85) 6 (90) 2 (88)
>4y 6 (100) 4 (100) 4 (100)
Total 40 41 18590 A.L. HARRIS et al.
I` on treatment (t=0.033, P<0.02, paired test). In
17 patients not receiving tamoxifen in the previous
2 months, SHBG levels rose from 56+23 (s.d.) to
69+32 (s.d.) nmol DHT bound P1- (P=0.004).
Prolactin
Prolactin levels before the start of treatment were
not significantly different between responders and
non-responders (Table I, Figure 4). However,
during treatment prolactin levels were
>500mlU -' in 14/40 non-responders and 2/35
responders (X2 9.53, P<0.01). Mean prolactin levels
were higher in non-responders (Table I). High
prolactin levels were associated with failure to
respond independently of high oestrone levels. Six
of 18 non-responders with an oestrone
> 120pmol -' had prolactin levels >500mlU -1,
whilst 8/22 non-responders with an oestrone level of
<120pmol -' had high prolactin levels. There was
a small but significant rise of prolactin in
responders during treatment.
Prolactin and oestrone in non-responders
Six of 40 responders had raised oestrone, prolactin
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Figure 4 Prolactin levels before and during treatment
with aminoglutethimide. The individual points are
values for patients who did not have samples taken
before treatment and are values on treatment. The
numbers are the numbers ofpatients.
or both, compared with 28/41 non-responders (X2
23.6, P<0.001) (Figure 5).
Discussion
This study shows that aminoglutethimide plus
hydrocortisone therapy produces oestrone and
oestradiol suppression in patients with advanced
postmenopausal breast cancer. In non-responders,
oestrone levels are higher on therapy than in
responders. This difference persists when maximum
or mean levels are analysed from serial data in
individual patients, and when compared at 1-3
months from the start of treatment. However,
comparison of data from responders and non-
responders on chronic treatment showed no
significant difference in oestrone levels. This
appears to be due to those patients with high
oestrone concentration progressing, having their
therapy changed and thus not being available for
assessment on chronic treatment.
We found that the presence of bulky liver
metastases is associated with high oestrone levels.
Variation in AG metabolism associated with liver
secondaries in unlikely to explain the high oestrone
levels, since we have found equivalent oestrone
suppression with doses of AG of 250mg 2x day, 3x
day or 4x day (Harris et al., 1982b). It is possible
that oestrone clearance is impaired by the bulky
liver secondaries, which would lead to higher
circulating levels of oestrone. In cirrhosis higher A4
androstenedione production and increased aro-
matisation of A4 androstenedione to oestrone have
been observed (Gordon et al., 1975; Kley et al.,
1976). It is interesting that the non-responders with
liver secondaries who had A4 androstenedione levels
measured had high values. The liver is a site that
responds poorly to endocrine therapy, although it is
often oestrogen receptor-positive (Maas & Jonat,
1981; King, 1975). Our observations on oestrone
suppression may partly account for this. We are
currently carrying out further investigations into the
association of liver metastases with high steroid
concentrations. Another steroid hormone, medroxy-
progesterone acetate, when given to patients with
advanced breast cancer, reaches higher plasma
levels in those with liver secondaries compared to
those without (Milano et al., 1982).
The liver deposits do not, however, account for
the majority of cases with high oestrone levels.
Kirscher et al. (1978) found that conversion of
androstenedione to oestrone accounts for only 65-
75% of total production rate of oestrone in women
with breast cancer versus 92-95% in controls. This
may explain the observation of Santen et al.
(1977a) and our observations that oestrone
concentrations are only about 60% suppressed,AMINOGLUTETHIMIDE INDUCED HORMONE SUPPRESSION AND RESPONSE TO THERAPY 591
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Figure 5 Oestrone and prolactin levels during treatment with aminoglutethimide. The individual points are
values for separate patients. Responders (A); non-responders (V). The oestrone value is the highest on
treatment measurement. The horizontal line represents the normal upper limit of prolactin of 5OOmlUI-1.
The vertical line is drawn through oestrone level of 120pmol1-1.
although AG inhibits aromatisation by 95%
(Santen et al., 1978). The site of production of the
rest of the oestrone is unknown. These workers also
found a subgroup of patients with much more
rapid oestrone clearance but with no distinguishing
clinical features. These metabolic differences in
oestrone metabolism may be associated with the
differences in hormone suppression by AG.
Body weight is another variable that affects
aromatisation (Vermeulen & Verdonck, 1978) but
non-responders with high oestrone levels were not
heavier than the other patients, and few were over
70kg. The weight difference in responders
compared with non-responders is in the opposite
direction to that required to explain the higher
oestrone levels. Similarly, years since the last
_ _ _ _ _ _ _592 A.L. HARRIS et al.
menstrual cycle and age, which are both associated
with increased aromatisation (Hemsell et al., 1974)
did not account for the difference.
The suppression of DHAS was more marked
than that of oestrone, but there were no differences
between responders and non-responders. Although
each patient did not have samples taken at each
time, it is shown in Figures 1 and 4 that the
hormones were measured in the same patients and
in the same blood samples. There is no difference in
DHAS, yet there is in oestrone. The DHAS acts as
an internal control.
Two other groups have compared smaller
numbers of responders and non-responders to AG
(Santen et al., 1982, Coombes et al., 1982).
Coombes et al. (1982) found no difference in
DHAS suppression in 8 responders compared with
6 non-responders. Santen et al. (1982) did not
describe serial values, but mean values in 55
patients.
These results for DHAS and oestrone contrast
with those of Santen et al. (1982). They found no
difference in percentage suppression of oestrone
levels between responders and non-responders, but
less DHAS suppression in non-responders. The
mean values for percentage suppression are,
however, very similar to ours. Santen et al. (1982)
did not express their results as plasma
concentrations, and if their series contained patients
with high on-treatment oestrone values, but with
normal percentage suppression, the apparent
difference between our results and those of Santen's
groups may be explained by a difference in means
of expression. Santen et al. (1982) also excluded
patients with bulky liver secondaries from their
study. On the other hand, Worgul et al. (1982) did
find lower urinary oestrone, in responders to
surgical adrenalectomy compared with non-
responders.
DHAS is suppressed by hydrocortisone, and not
by AG alone (Harris et al., 1982c). Thus, the high
DHAS in non-responders in the series of Santen et
al. (1982) may be reflection of the mode of
administration of hydrocortisone. They gave 20mg
in the evening and then 10mg in the morning and
10mg in the afternoon. We gave 20mg 12-hourly,
which may be more effective in producing DHAS
suppression at time of sample because of the larger
morning dose. Their results with DHAS may
therefore be a reflection of stress in progressing
patients.
We are able to confirm Murray's (1981)
observation that AG and hydrocortisone suppress
testosterone levels. Santen et al. (1982) did not
observe this but they only looked at 6 patients.
SHBG was measured as a marker of
oestrogenicity of the peripheral hormone
environment, since SHBG levels are raised by
oestrogens and lowered by androgens (Anderson,
1974). However, we found that SHBG rose in those
patients who had not had tamoxifen in the 2
months before starting AG. SHBG is induced by
other anticonvulsants (AG was originally marketed
as an anticonvulsant) and may be a marker for
liver enzyme induction (Victor et al., 1977).
Tamoxifen produces rises in SHBG (Sakai et al.,
1978) and patients who had tamoxifen in the
previous two months before starting AG had higher
levels than the other patients. These levels fell on
therapy with AG but this may just be a reflection
on the long tissue half-life of tamoxifen. Thus
SHBG levels did not differ between responders and
non-responders and were not correlated with
oestrone levels.
Prolactin levels before the start of treatment did
not differ between responders and non-responders.
The small significant rise in responders may be a
response to increased thyrotrophin releasing
hormone, since AG produces a rise in thyroid-
stimulating hormone (Santen et al., 1977b).
However, prolactin levels were found to be above
5OOmlUl- in 14 of the non-responders. A rise of
prolactin in patients with progressive disease has
been reported during therapy with dexamethasone
in 6 patients (Borkowski et al., 1977), but not
during progression while on tamoxifen (Golder et
al., 1976; Willis et al., 1977).
The prolactin and oestrone results suggest
subgroups of patients not responding to AG who
may benefit from adding other endocrine therapy,
i.e. tamoxifen for those with high oestrone, or
bromocryptine for those with high prolactin.
Although bromocryptine alone is ineffective
(European Breast Cancer Group, 1972), it has been
shown to increase response rates to chemotherapy
when given to patients with high prolactin (Nagel
et al., 1982). Combination endocrine therapy has
not been shown to produce an increase in response
rates (Tormey et al., 1976; Ward, 1977), but if only
a subgroup of patients benefit, then the numbers in
most trials have been too small to detect even a 2-
fold difference with 90% confidence. Many of the
non-responders will be oestrogen receptor negative,
but only 50% of oestrogen receptor positive
patients respond to first line endocrine therapy or
to endocrine therapy with AG (Lawrence et al.,
1980). Some of these oestrogen receptor-positive
patients may fail to respond because of inadequate
manipulation of the endocrine environment. This
study shows that there are differences in the
peripheral endocrine environment within one month
of starting treatment in non-responders compared
with responders. By using peripheral hormone
assays, it is possible that "logical" endocrineAMINOGLUTETHIMIDE INDUCED HORMONE SUPPRESSION AND RESPONSE TO THERAPY 593
therapy might be devised for individual patients.
Such an approach will need to be studied in a
prospective trial.
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